Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REX-001 versus placebo for ischemic ulcers in diabetic chronic limb-threatening ischemia
NL-OMON55357Phase 3Active, not recruiting
- Sponsor
- Ixaka
- Start
- Oct 2019
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic limb-threatening ischemia (CLTI), arteriosclerosis obliterans and diabetes mellitus (DM) comparing REX-001 with Placebo (2 arms). Primary endpoint: Change in Rutherford classification to category 4 or lower at 12 months. Started Oct 2019; status: active, not recruiting.
02
Drugs
rexmyelocel-T
03
Conditions
chronic limb-threatening ischemia (CLTI)arteriosclerosis obliteransdiabetes mellitus (DM)
Beyond the preview
Go deeper on NL-OMON55357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55357.